Prostaglandin E2 and myocarditis; friend or foe?

[Display omitted] This review article summarizes the role of prostaglandin E2 (PGE2) and its receptors (EP1-EP4) as it relates to the inflammatory cardiomyopathy, myocarditis. During the COVID-19 pandemic, the onset of myocarditis in a subset of patients prompted a debate on the use of nonsteroidal...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical pharmacology 2023-11, Vol.217, p.115813-115813, Article 115813
Main Authors: Bryson, Timothy D., Harding, Pamela
Format: Article
Language:English
Subjects:
Cardiomyopathy
Cardiovascular disease
COVID-19
Heart
Inflammation
Myocarditis
NSAIDs
Prostaglandin E2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] This review article summarizes the role of prostaglandin E2 (PGE2) and its receptors (EP1-EP4) as it relates to the inflammatory cardiomyopathy, myocarditis. During the COVID-19 pandemic, the onset of myocarditis in a subset of patients prompted a debate on the use of nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, which act to inhibit the actions of prostaglandins. This review aims to further understanding of the role of PGE2 in the pathogenesis or protection of the myocardium in myocarditis. Inflammatory cardiomyopathies encompass a broad spectrum of disorders, all characterized by cardiac inflammation. Therefore, for the purpose of this review, the authors have placed particular emphasis on etiologies of myocarditis where effects of PGE2 have been documented.
ISSN:0006-2952
1873-2968
DOI:10.1016/j.bcp.2023.115813